Becton, Dickinson and Company (BDX), or BD, comprises BD Medical and BD Lifesciences segments. The BD Medical business generated revenues of ~$8.7 billion in fiscal 2016, which ended September 30, 2016. The segment consists of three divisions: Medication and Procedural Solutions (or MPS), which includes Medication Management Consumables and Infection Prevention Solutions; Medication Management Solutions (or MMS); and Diabetes Care and Pharmaceuticals.
For a brief overview of BD’s Medical segment’s recent earnings results, please read Becton Dickinson’s BD Medical Segment Sales in Fiscal 3Q16.
BD Medical segment’s core focus areas
BD Medical leads in all of its key strategic areas, as shown in the chart above. The company is expanding across the markets served as well as focusing on redefining its focus areas according to their potential growth.
BD plans to focus on creating value across the BD Medical care continuum, which would advance its disease management and digital health solutions.
Among the other major medical device players in the US, Medtronic (MDT), Abbott Laboratories (ABT), and Zimmer Biomet Holdings (ZBH) have also been focused on evolving their business models to gain a strong position in the evolving healthcare industry.
Investors interested in broad-based gain exposure to BDX can invest in the Vanguard Growth ETF (VUG).
BD Medical growth strategy
BD Medical’s key growth strategy is focused on four strategic pillars. The company plans to focus on re-inventing its medication management process across the care continuum, preventing infections and improving safety for healthcare workers, advancing the treatment of diabetes and other chronic diseases, and expanding around the world.